返回 
加入收藏
奈达铂联合紫杉醇治疗晚期宫颈癌的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 奈达铂联合紫杉醇治疗晚期宫颈癌的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察奈达铂联合紫杉醇治疗晚期宫颈癌的疗效和安全性。方法： 100例晚期宫颈癌患者随机分为对照组（50例）和观察组（50例）。两组患者均采用6MV直线加速器外放射联合腔内后装照射。在此基础上，对照组患者静脉滴注顺铂注射液20 mg/m2，d1+紫杉醇注射液35 mg/m2，d1，3 h内滴完；观察组患者静脉滴注注射用奈达铂 20 mg/m2，d1+紫杉醇注射液（用法用量同对照组）。两组均以1周为1个周期，共治疗6个周期。观察两组患者的近期疗效，治疗前后血管内皮生长因子A（VEGF-A）、VEGF-C、VEGF-D水平和微淋巴管密度（LVD）、微血管密度（MVD）及毒副反应发生情况。结果：观察组患者总有效率（52.00％）、疾病控制率（86.00％）均显著高于对照组（分别为32.00％、66.00％），差异均有统计学意义（P＜0.05）。治疗后，两组患者VEGF-A、VEGF-C、VEGF-D水平和LVD、MVD均显著低于同组治疗前，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。观察组患者血小板减少发生率显著高于对照组，恶心呕吐发生率显著低于对照组，差异均有统计学意义（P＜0.05）。结论：奈达铂联合紫杉醇可提高晚期宫颈癌患者的近期疗效，降低VEGF水平及抑制肿瘤血管生成，减少胃肠道反应，但应注意血小板毒性反应。 |
| ABSTRACT： | OBJECTIVE: To observe therapeutic efficacy and safety of nedaplatin combined with paclitaxel in the treatment of advanced cervical cancer. METHODS： Totally 100 patients with advanced cervical cancer were randomly divided into observation group （50 cases） and control group （50 cases）. Both groups were given 6MV linear accelerator radiotherapy combined with intracavitary irradiation. Based on it， control group was additionally given Cisplatin injection 20 mg/m2，d1+Paclitaxel injection 35 mg/m2， d1 intravenously within 3 h. Observation group was additionally given Nedaplatin for injection 20 mg/m2，d1+Paclitaxel injection intravenously （same usage and dosage as control group）. A treatment course lasted for a week， and both groups received 6 courses of treatment. Short-term efficacies of 2 groups were observed， and the levels of vascular endothelial growth factor A （VEGF-A）， VEGF-C and VEGF-D， lymphatic microvessel density （LVD）， microvessel density （MVD）， toxic reaction were also observed before and after treatment. RESULTS: Total response rate （52.00％ vs. 32.00％） and disease control rate （86.00％ vs. 66.00％） of observation group were significantly higher than those of control group， with statistical significance（P＜0.05）. After treatment， the levels of VEGF-A， VEGF-C and VEGF-D， LVD， MVD in 2 groups were significantly lower than before treatment， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. The incidence of thrombocytopenia in observation group was significantly higher than control group， and the incidence of nausea and vomiting was significantly lower than control group， with statistical significance （P＜0.05）. CONCLUSIONS: Nedaplatin combined with paclitaxel can improve short-term efficacy of patients with advanced cervical cancer， reduce gastrointestinal reaction， VEGF level and inhibit the generation of tumor vessel， but great importance should be attached to platelet toxic reaction. |
| 期刊： | 2017年第28卷第15期 |
| 作者： | 孙桂霞，杨少琴 |
| AUTHORS： | SUN Guixia，YANG Shaoqin |
| 关键字： | 晚期宫颈癌；奈达铂；紫杉醇；顺铂；疗效；安全性 |
| KEYWORDS： | Advanced cervical cancer； Nedaplatin； Paclitaxel； Gsplatin； Therapeutic efficacy； Safety |
| 阅读数： | 670 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
